TotalMarketCap

DBV Technologies

DBVTNasdaq FranceHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$614.945 M

$9.78 -1.61%

Close of 6 Nov 2026

As of 6 Nov 2026, DBV Technologies (DBVT) has a market capitalization of $614.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$5.64M

#3244 by revenue

Earnings

-$146.9M

Loss-making

Shares outstanding

314,388,807

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #584D Molecular TherapeuticsFDMT$621.8M
  2. #59Candel TherapeuticsCADL$615.6M
  3. #60DBV TechnologiesDBVT$614.9M
  4. #61Iambic TherapeuticsIAM$550.1M
  5. #62Valneva SEVALN$532.9M

What if DBV Technologies were worth as much as…

Open the what-if tool →

Gold $28.2T

$449,075.69

Per share 45,918× higher

Bitcoin $1.53T

$24,298.70

Per share 2,485× higher

Apple $5.02T

$79,770.38

Per share 8,156× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for DBV Technologies are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.